Cargando…
Immediate-release tofacitinib reduces insulin resistance in non-diabetic active rheumatoid arthritis patients: A single-center retrospective study
BACKGROUND: An increased risk of insulin resistance (IR) has been identified in rheumatoid arthritis (RA), a chronic inflammatory disorder with elevated levels of pathogenic cytokines. Biologics targeting proinflammatory cytokines can control the disease and improve insulin sensitivity in RA. Althou...
Autores principales: | Wang, Chrong-Reen, Tsai, Hung-Wen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210542/ https://www.ncbi.nlm.nih.gov/pubmed/35800413 http://dx.doi.org/10.4239/wjd.v13.i6.454 |
Ejemplares similares
-
Anti- and non-tumor necrosis factor-α-targeted therapies effects on insulin resistance in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
por: Wang, Chrong-Reen, et al.
Publicado: (2021) -
Extended-release tofacitinib for refractory Behçet disease: A case report
por: Wang, Chrong-Reen, et al.
Publicado: (2022) -
Recombinant Soluble TNF‐α Receptor Fusion Protein Therapy Reduces Insulin Resistance in Non‐Diabetic Active Rheumatoid Arthritis Patients
por: Wang, Chrong‐Reen, et al.
Publicado: (2020) -
Severe COVID-19 pneumonia in patients with rheumatoid arthritis under B-cell depletion therapy
por: Wang, Chrong-Reen, et al.
Publicado: (2023) -
Major depressive disorders in patients with inflammatory bowel disease and rheumatoid arthritis
por: Haider, Maryam Bilal, et al.
Publicado: (2023)